Roseau J-B, Berard H, N'guyen Huy Thuy G, Rocher F, Legodec J, Chouaid C
Service de Pneumologie, HIA Sainte-Anne, Toulon Armées, France.
Rev Mal Respir. 2008 Nov;25(9):1142-4. doi: 10.1016/s0761-8425(08)74987-8.
The haematological side effects of antitubercular drugs are not well known. We report the observation of a patient who received Rifater for the treatment of pulmonary tuberculosis. After one month of treatment, he developed an acute pulmonary infection, with neutropenia (1218/microl) and thrombocytopenia (109,000/microl), requiring suspension of his antitubercular drugs. After the reintroduction of he again developed thrombocytopenia (6,000/microl) associated with bleeding and required treatment with intravenous immunoglobulin. The introduction of a combination of moxifloxacin, isoniazid, pyrazinamide, and ethambutol was followed by a new relapse of the thrombocytopenia. Responsibility of pyrazinamide was then suspected and later confirmed by the evolution of platelet levels after stopping and reintroducing this antibiotic. This is the third reported case of pyrazinamide induced thrombocytopenia, whose frequency is probably underestimated because of the use of compound treatment.
抗结核药物的血液学副作用尚不为人所知。我们报告了一名接受卫非特治疗肺结核患者的观察情况。治疗一个月后,他出现了急性肺部感染,伴有中性粒细胞减少(1218/微升)和血小板减少(109,000/微升),需要停用抗结核药物。再次用药后,他又出现了与出血相关的血小板减少(6,000/微升),并需要静脉注射免疫球蛋白治疗。引入莫西沙星、异烟肼、吡嗪酰胺和乙胺丁醇联合用药后,血小板减少症再次复发。随后怀疑是吡嗪酰胺的责任,后来通过停用和重新引入这种抗生素后血小板水平的变化得到证实。这是第三例报告的吡嗪酰胺诱导的血小板减少症病例,由于使用复方治疗,其发生率可能被低估。